Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Introduction: Associations of hormone-receptor positive breast cancer with excess adiposity are reasonably well characterized; however, uncertainty remains regarding the association of body mass index (BMI) with hormone-receptor negative malignancies, and possible interactions by hormone replacement therapy (HRT) use. Methods: Within the European EPIC cohort, Cox proportional hazards models were used to describe the relationship of BMI, waist and hip circumferences with risk of estrogen-receptor (ER) negative and progesterone-receptor (PR) negative (n = 1,021) and ER+PR+ (n = 3,586) breast tumors within five-year age bands. Among postmenopausal women, the joint effects of BMI and HRT use were analyzed. Results: For risk of ER-PR- tumors, there was no association of BMI across the age bands. However, when analyses were restricted to postmenopausal HRT never users, a positive risk association with BMI (third versus first tertile HR = 1.47 (1.01 to 2.15)) was observed. BMI was inversely associated with ER+PR+ tumors among women aged ≤49 years (per 5 kg/m 2 increase, HR = 0.79 (95%CI 0.68 to 0.91)), and positively associated with risk among women ≥65 years (HR = 1.25 (1.16 to 1.34)). Adjusting for BMI, waist and hip circumferences showed no further associations with risks of breast cancer subtypes. Current use of HRT was significantly associated with an increased risk of receptor-negative (HRT current use compared to HRT never use HR: 1.30 (1.05 to 1.62)) and positive tumors (HR: 1.74 (1.56 to 1.95)), although this risk increase was weaker for ER-PR- disease (P he t = 0.035). The association of HRT was significantly stronger in the leaner women (BMI ≤22.5 kg/m 2) than for more overweight women (BMI ≥25.9 kg/m 2) for, both, ER-PR- (HR: 1.74 (1.15 to 2.63)) and ER+PR+ (HR: 2.33 (1.84 to 2.92)) breast cancer and was not restricted to any particular HRT regime. Conclusions: An elevated BMI may be positively associated with risk of ER-PR- tumors among postmenopausal women who never used HRT. Furthermore, postmenopausal HRT users were at an increased risk of ER-PR- as well as ER+PR+ tumors, especially among leaner women. For hormone-receptor positive tumors, but not for hormone-receptor negative tumors, our study confirms an inverse association of risk with BMI among young women of premenopausal age. Our data provide evidence for a possible role of sex hormones in the etiology of hormone-receptor negative tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Riboli, E., Hunt, K., Slimani, N., Ferrari, P., Norat, T., Fahey, M., Charrondière, U., Hémon, B., Casagrande, C., Vignat, J., et al. (2002) · Public Health Nutrition · doi:10.1079/phn2002394 · Cited by 1,866
Self-citationValidity of self-reported height and weight in 4808 EPIC–Oxford participants
Spencer, E. A., Appleby, P. N., Davey, G. K., & Key, T. J. (2002) · Public Health Nutrition · doi:10.1079/phn2001322 · Cited by 1,082
Self-citationControl of mammary stem cell function by steroid hormone signalling
Asselin-Labat, M.-L., Vaillant, F., Sheridan, J. M., Pal, B., Wu, D., Simpson, E. R., Yasuda, H., Smyth, G. K., Martin, T. J., Lindeman, G. J., et al. (2010) · Nature · doi:10.1038/nature09027 · Cited by 693
Review of survival analyses published in cancer journals
Altman, D., De Stavola, B., Love, S., & Stepniewska, K. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.364 · Cited by 438
Cited by
Bhaskaran, K., Douglas, I., Forbes, H., dos-Santos-Silva, I., Leon, D. A., & Smeeth, L. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60892-8 · Cited by 1,707
Adiposity and cancer at major anatomical sites: umbrella review of the literature
Kyrgiou, M., Kalliala, I., Markozannes, G., Gunter, M. J., Paraskevaidis, E., Gabra, H., Martin-Hirsch, P., & Tsilidis, K. K. (2017) · BMJ · doi:10.1136/bmj.j477 · Cited by 803
Adiposity and cancer risk: new mechanistic insights from epidemiology
Renehan, A. G., Zwahlen, M., & Egger, M. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3967 · Cited by 654
Reproductive risk factors and breast cancer subtypes: a review of the literature
Anderson, K. N., Schwab, R. B., & Martinez, M. E. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-2852-7 · Cited by 378
Pathogenesis, prevention, diagnosis and treatment of breast cancer
Shah, R. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i3.283 · Cited by 329
Risk determination and prevention of breast cancer
Howell, A., Anderson, A. S., Clarke, R. B., Duffy, S. W., Evans, D. G., Garcia-Closas, M., Gescher, A. J., Key, T. J., Saxton, J. M., & Harvie, M. N. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0446-2 · Cited by 327
Self-citationde Villiers, T. J., Pines, A., Panay, N., Gambacciani, M., Archer, D. F., Baber, R. J., Davis, S. R., Gompel, A. A., Henderson, V. W., Langer, R., et al. (2013) · Climacteric · doi:10.3109/13697137.2013.795683 · Cited by 298
De Ridder, J., Julián-Almárcegui, C., Mullee, A., Rinaldi, S., Van Herck, K., Vicente-Rodríguez, G., & Huybrechts, I. (2016) · Cancer Causes & Control · doi:10.1007/s10552-015-0709-y · Cited by 36
Self-citation
Metadata
- Authors
- Ritte, R., Lukanova, A., Berrino, F., Dossus, L., Tjønneland, A., Olsen, A., Overvad, T. F., Overvad, K., Clavel-Chapelon, F., Fournier, A., Fagherazzi, G., Rohrmann, S., Teucher, B., Boeing, H., Aleksandrova, K., Trichopoulou, A., Lagiou, P., Trichopoulos, D., Palli, D., Sieri, S., Panico, S., Tumino, R., Vineis, P., Quirós, J. R., Buckland, G., Sánchez, M.-J., Amiano, P., Chirlaque, M.-D., Ardanaz, E., Sund, M., Lenner, P., Bueno-de-Mesquita, B., van Gils, C. H., Peeters, P. H., Krum-Hansen, S., Gram, I. T., Lund, E., Khaw, K.-T., Wareham, N., Allen, N. E., Key, T. J., Romieu, I., Rinaldi, S., Siddiq, A., Cox, D., Riboli, E., & Kaaks, R.
- Venue
- Breast Cancer Research
- Published
- 2012-05-14
- Volume
- 14
- Issue
- 3
- Pages
- R76-R76
- ISSN
- 1465-5411 (ISSN-L)
- 1465-542X
- OpenAlex
- W2126396090
- Cited by
- 128
- References
- 4
- FWCI
- 5.68
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.